CA2659413C - Muteines de lipocaline lacrymale et procedes permettant d'obtenir lesdites muteines - Google Patents
Muteines de lipocaline lacrymale et procedes permettant d'obtenir lesdites muteines Download PDFInfo
- Publication number
- CA2659413C CA2659413C CA2659413A CA2659413A CA2659413C CA 2659413 C CA2659413 C CA 2659413C CA 2659413 A CA2659413 A CA 2659413A CA 2659413 A CA2659413 A CA 2659413A CA 2659413 C CA2659413 C CA 2659413C
- Authority
- CA
- Canada
- Prior art keywords
- fwdarw
- mutein
- glu
- leu
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La présente invention concerne de nouvelles mutéines dérivées de lipocaline lacrymale humaine. L'invention concerne également une molécule d'acide nucléique correspondante codant pour une telle mutéine, et un procédé permettant de la produire. L'invention concerne en outre un procédé de production d'une telle mutéine. Enfin, l'invention concerne une composition pharmaceutique comprenant une telle mutéine de lipocaline, ainsi que diverses utilisations de la mutéine.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82107306P | 2006-08-01 | 2006-08-01 | |
US60/821,073 | 2006-08-01 | ||
US91201307P | 2007-04-16 | 2007-04-16 | |
US60/912,013 | 2007-04-16 | ||
PCT/EP2007/057971 WO2008015239A2 (fr) | 2006-08-01 | 2007-08-01 | Mutéines de lipocaline lacrymale et procédés permettant d'obtenir lesdites mutéines |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2659413A1 CA2659413A1 (fr) | 2008-02-07 |
CA2659413C true CA2659413C (fr) | 2016-06-14 |
Family
ID=38997508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2659413A Active CA2659413C (fr) | 2006-08-01 | 2007-08-01 | Muteines de lipocaline lacrymale et procedes permettant d'obtenir lesdites muteines |
Country Status (14)
Country | Link |
---|---|
US (4) | US8313924B2 (fr) |
EP (1) | EP2046820B1 (fr) |
JP (1) | JP5608368B2 (fr) |
KR (1) | KR101516023B1 (fr) |
CN (2) | CN105112477A (fr) |
AT (1) | ATE485304T1 (fr) |
AU (1) | AU2007280398B2 (fr) |
CA (1) | CA2659413C (fr) |
DE (1) | DE602007009995D1 (fr) |
DK (1) | DK2046820T3 (fr) |
HK (1) | HK1131167A1 (fr) |
MX (1) | MX2009001203A (fr) |
SG (1) | SG173332A1 (fr) |
WO (1) | WO2008015239A2 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2659413C (fr) * | 2006-08-01 | 2016-06-14 | Pieris Ag | Muteines de lipocaline lacrymale et procedes permettant d'obtenir lesdites muteines |
US9212208B2 (en) * | 2008-01-30 | 2015-12-15 | Pieris Ag | Muteins with tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the same |
US20090274623A1 (en) * | 2008-01-30 | 2009-11-05 | General Electric Company | In vivo imaging agents for met receptor tyrosine kinase |
IN2012DN00407A (fr) * | 2009-08-05 | 2015-08-21 | Pieris Ag | |
US9549968B2 (en) * | 2009-12-07 | 2017-01-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target |
TR201906295T4 (tr) | 2010-06-08 | 2019-05-21 | Astrazeneca Ab | IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri. |
KR20130096731A (ko) * | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | 조건부 활성 치료적 단백질을 평가,확인 또는 진화시키는 방법 |
EP2621538B1 (fr) * | 2010-09-28 | 2015-12-16 | Amylin Pharmaceuticals, LLC | Polypeptides génétiquement modifiés ayant une durée d'action renforcée |
WO2012136685A1 (fr) | 2011-04-04 | 2012-10-11 | Pieris Ag | Procédés et compositions pour thérapie anti-vegf et anti-c-met |
WO2012172054A1 (fr) | 2011-06-16 | 2012-12-20 | Scil Proteins Gmbh | Protéines d'ubiquitine multimères modifiées se liant au vegf-a |
WO2013068590A1 (fr) * | 2011-11-11 | 2013-05-16 | Pieris Ag | Mutéines de lipocaline utilisées comme antagonistes du vegf destinées à être utilisées pour traiter des maladies provoquées ou favorisées par une vascularisation accrue |
AU2012350660B2 (en) | 2011-12-13 | 2018-01-25 | Astrazeneca Ab | Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors |
ES2749620T3 (es) | 2011-12-30 | 2020-03-23 | Halozyme Inc | Variantes de polipéptidos de PH20, formulaciones y usos de los mismos |
US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
EP2920202B1 (fr) * | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Nouveaux polypeptides se liant specifiquement, et leur utilisation |
US20140149578A1 (en) * | 2012-11-26 | 2014-05-29 | Go Daddy Operating Company, LLC | Method For Testing Methods of Accelerating Content Delivery |
US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
SG11201505856TA (en) * | 2013-03-14 | 2015-08-28 | Daiichi Sankyo Co Ltd | Novel binding proteins for pcsk9 |
TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
US9388239B2 (en) * | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
EP3789397B1 (fr) | 2014-05-22 | 2023-12-06 | Pieris Pharmaceuticals GmbH | Nouveaux polypeptides de liaison spécifique et leurs utilisations |
US11382963B2 (en) | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
EP3064507A1 (fr) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Protéines de fusion comprenant une protéine de liaison et un polypeptide interleukine-15 ayant une affinité réduite pour IL15ra et leurs utilisations thérapeutiques |
CN107636014B (zh) * | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
WO2016177762A1 (fr) | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Protéines spécifiques de cd137 |
EP3298029A1 (fr) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Mutéines de la lipocaline 2 humaine avec affinité pour glypican-3 (gpc3) |
ES2938525T3 (es) * | 2015-05-18 | 2023-04-12 | Pieris Pharmaceuticals Gmbh | Polipéptido de fusión anticanceroso |
WO2018015380A1 (fr) | 2016-07-18 | 2018-01-25 | Philippe Ulsemer | Micro-organismes naturels qui sont naturellement capables de se lier à des toxines et/ou des récepteurs de toxine |
EP3583120B1 (fr) | 2017-02-17 | 2022-10-05 | Denali Therapeutics Inc. | Polypeptides de liaison au récepteur de transferrine modifiés |
US20210269499A1 (en) | 2018-06-21 | 2021-09-02 | Technische Universitaet Muenchen | Hepatitis b and/or hepatitis d-permissive cells and animals |
SG11202106353VA (en) | 2019-02-26 | 2021-07-29 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
JP2022526524A (ja) | 2019-03-29 | 2022-05-25 | アストラゼネカ・アクチエボラーグ | 喘息の処置のためのリポカリンムテイン |
JP2022526367A (ja) | 2019-03-29 | 2022-05-24 | ピエリス ファーマシューティカルズ ゲーエムベーハー | リポカリンムテインの吸入投与 |
CA3199479A1 (fr) | 2020-12-18 | 2022-06-23 | Mary Fitzgerald | Formulation de poudre seche de muteine de la lipocaline pour le traitement de l'asthme |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087925A2 (fr) * | 2000-05-16 | 2001-11-22 | Bolder Biotechnology, Inc. | Procede de repliement de proteines renfermant des residus de cysteine libre |
US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
EP1430136A1 (fr) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteines d'apolipoproteine d |
WO2003029462A1 (fr) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
EP1658308A1 (fr) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteines de la proteine liant la biline ayant une affinite pour une cible donnee |
EP2899277A1 (fr) | 2004-11-26 | 2015-07-29 | Pieris AG | Composé à affinité pour l'antigène associé aux lymphocytes T cytotoxiques (CTLA-4) |
US8598317B2 (en) | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
CA2659413C (fr) * | 2006-08-01 | 2016-06-14 | Pieris Ag | Muteines de lipocaline lacrymale et procedes permettant d'obtenir lesdites muteines |
-
2007
- 2007-08-01 CA CA2659413A patent/CA2659413C/fr active Active
- 2007-08-01 AU AU2007280398A patent/AU2007280398B2/en active Active
- 2007-08-01 DK DK07788139.9T patent/DK2046820T3/da active
- 2007-08-01 AT AT07788139T patent/ATE485304T1/de active
- 2007-08-01 SG SG2011047883A patent/SG173332A1/en unknown
- 2007-08-01 JP JP2009522275A patent/JP5608368B2/ja active Active
- 2007-08-01 MX MX2009001203A patent/MX2009001203A/es active IP Right Grant
- 2007-08-01 EP EP07788139A patent/EP2046820B1/fr active Active
- 2007-08-01 KR KR1020097004449A patent/KR101516023B1/ko active IP Right Grant
- 2007-08-01 CN CN201510431417.8A patent/CN105112477A/zh active Pending
- 2007-08-01 CN CN201510013379.4A patent/CN104650213A/zh active Pending
- 2007-08-01 DE DE602007009995T patent/DE602007009995D1/de active Active
- 2007-08-01 US US12/309,820 patent/US8313924B2/en active Active
- 2007-08-01 WO PCT/EP2007/057971 patent/WO2008015239A2/fr active Application Filing
-
2009
- 2009-11-19 HK HK09110805.5A patent/HK1131167A1/zh unknown
-
2012
- 2012-09-14 US US13/616,815 patent/US9221887B2/en active Active
-
2015
- 2015-12-28 US US14/981,589 patent/US10046027B2/en active Active
-
2018
- 2018-07-10 US US16/031,663 patent/US20190015477A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2046820B1 (fr) | 2010-10-20 |
CN105112477A (zh) | 2015-12-02 |
US10046027B2 (en) | 2018-08-14 |
WO2008015239A3 (fr) | 2008-08-21 |
DK2046820T3 (da) | 2011-02-07 |
US20190015477A1 (en) | 2019-01-17 |
SG173332A1 (en) | 2011-08-29 |
JP2009545301A (ja) | 2009-12-24 |
US20130017996A1 (en) | 2013-01-17 |
ATE485304T1 (de) | 2010-11-15 |
KR101516023B1 (ko) | 2015-04-30 |
WO2008015239A2 (fr) | 2008-02-07 |
JP5608368B2 (ja) | 2014-10-15 |
EP2046820A2 (fr) | 2009-04-15 |
CN104650213A (zh) | 2015-05-27 |
AU2007280398B2 (en) | 2012-05-10 |
AU2007280398A1 (en) | 2008-02-07 |
CA2659413A1 (fr) | 2008-02-07 |
US20160256525A1 (en) | 2016-09-08 |
MX2009001203A (es) | 2009-06-01 |
DE602007009995D1 (de) | 2010-12-02 |
US9221887B2 (en) | 2015-12-29 |
US8313924B2 (en) | 2012-11-20 |
HK1131167A1 (zh) | 2010-01-15 |
KR20090090295A (ko) | 2009-08-25 |
US20090305982A1 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2659413C (fr) | Muteines de lipocaline lacrymale et procedes permettant d'obtenir lesdites muteines | |
US9751920B2 (en) | Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same | |
US10618941B2 (en) | Muteins of human lipocalin 2 (Lcn2,hNGAL) with affinity for a given target | |
JP6100694B2 (ja) | グリピカン−3(gpc3)に対して親和性を有するヒトリポカリン2の突然変異タンパク質 | |
EP2646552B1 (fr) | Mutéines dérivées de la lipocaline 2 humaine à affinité pour ctla-4 | |
ES2354653T3 (es) | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. | |
AU2011203057B2 (en) | Muteins of tear lipocalin and methods for obtaining the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |